Home>
US Stocks>
Esperion Therapeutics Share Price

Esperion Therapeutics share price today

(ESPR)

Esperion Therapeutics share price is $2.21 & ₹191.40 as on 18 Jan 2025, 2.30 'hrs' IST

$2.21

▲

-0.05

(-2.21%)

Market is closed - opens 8 PM, 21 Jan 2025

View live Esperion Therapeutics share price in Dollar and Rupees. Guide to invest in Esperion Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Esperion Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Esperion Therapeutics share price movements

Today's Low: $2.18
Today's High: $2.31
$2.21
1.36%
Downside
Day's Volatility :5.63%
Upside
4.33%
52 Weeks Low: $1.58
52 Weeks High: $3.94
$2.21
28.51%
Downside
52 Weeks Volatility :59.9%
Upside
43.91%

Esperion Therapeutics Returns

Period	Esperion Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	7.28%	-8.5%	0.0%
6 Months	-8.3%	-5.2%	0.0%
1 Year	2.79%	0.5%	0.0%
3 Years	-41.38%	6.5%	-14.2%

Esperion Therapeutics Key Statistics

in dollars & INR

Previous Close	$2.26
Open	$2.25
Today's High	$2.31
Today's Low	$2.1799
Market Capitalization	$435.4M
Today's Volume	$2.5M
52 Week High	$3.94
52 Week Low	$1.58
Revenue TTM	$295.5M
EBITDA	$16.5M
Earnings Per Share (EPS)	$-0.66
Profit Margin	-29.37%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-260.79%

How to invest in Esperion Therapeutics from India?

It is very easy for Indian residents to invest directly in Esperion Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Esperion Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Esperion Therapeutics or ESPR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Esperion Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Esperion Therapeutics shares which would translate to 0.392 fractional shares of Esperion Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Esperion Therapeutics, in just a few clicks!

Returns in Esperion Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Esperion Therapeutics investment value today

Current value as on today

₹1,07,024

Returns

₹7,024

(+7.02%)

Returns from Esperion Therapeutics Stock

₹2,791 (+2.79%)

Dollar Returns

₹4,233 (+4.23%)

Indian investors sentiment towards Esperion Therapeutics

-22%

Period: Oct 20, 2024 to Jan 18, 2025. Change in 30 Days versus previous period

Search volume for Esperion Therapeutics on INDmoney from India has reduced in the last 30 days as on Jan 19, 2025. -22% less investors are searching Esperion Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Esperion Therapeutics

Wasatch Advisors LP
11.85%
BlackRock Inc
7.24%
Vanguard Group Inc
6.62%
Bellevue Group AG
5.05%
Two Seas Capital LP
3.34%
Geode Capital Management, LLC
2.20%

Analyst Recommendation on Esperion Therapeutics

Buy

71%Buy

28%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Esperion Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Esperion Therapeutics

What analysts predicted

Upside of 222.68%

Target:

$7.13

Current:

$2.21

Insights on Esperion Therapeutics

Price Movement
In the last 7 days, ESPR stock has moved down by -5.6%
Decreasing Revenue
Revenue is down for the last 3 quarters, 137.73M → 51.63M (in $), with an average decrease of 38.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -61.92M → -29.52M (in $), with an average increase of 109.7% per quarter
ESPR vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 92.8% return, outperforming this stock by 83.4%
ESPR vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 225.8% return, outperforming this stock by 266.6%
Price to Sales
ForESPR every $1 of sales, investors are willing to pay $1.2, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.7 for every $1 of sales.

Esperion Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$184.5M	-
Net Income	$-201.8M	↑ 20.85%
Net Profit Margin	-109.4%	-

	FY19	Y/Y Change
Revenue	$148.4M	↓ 19.57%
Net Income	$-109.0M	↓ 45.98%
Net Profit Margin	-73.48%	↑ 35.92%

	FY20	Y/Y Change
Revenue	$227.5M	↑ 53.37%
Net Income	$-166.2M	↑ 52.44%
Net Profit Margin	-73.04%	↑ 0.44%

	FY21	Y/Y Change
Revenue	$78.4M	↓ 65.52%
Net Income	$-318.8M	↑ 91.84%
Net Profit Margin	-406.42%	↓ 333.38%

	FY22	Y/Y Change
Revenue	$75.5M	↓ 3.79%
Net Income	$-287.8M	↓ 9.73%
Net Profit Margin	-381.34%	↑ 25.08%

	FY23	Y/Y Change
Revenue	$116.3M	↑ 54.14%
Net Income	$-209.2M	↓ 27.3%
Net Profit Margin	-179.87%	↑ 201.47%

	Q2 FY23	Q/Q Change
Revenue	$25.8M	↑ 5.99%
Net Income	$-49.9M	↓ 44.03%
Net Profit Margin	-193.65%	↑ 173.07%

	Q3 FY23	Q/Q Change
Revenue	$34.0M	↑ 31.73%
Net Income	$-41.3M	↓ 17.39%
Net Profit Margin	-121.43%	↑ 72.22%

	Q4 FY23	Q/Q Change
Revenue	$32.3M	↓ 5.06%
Net Income	$-56.3M	↑ 36.59%
Net Profit Margin	-174.71%	↓ 53.28%

	Q1 FY24	Q/Q Change
Revenue	$137.7M	↑ 327.09%
Net Income	$61.0M	↓ 208.3%
Net Profit Margin	44.3%	↑ 219.01%

	Q2 FY24	Q/Q Change
Revenue	$73.8M	↓ 46.39%
Net Income	$-61.9M	↓ 201.48%
Net Profit Margin	-83.87%	↓ 128.17%

	Q3 FY24	Q/Q Change
Revenue	$51.6M	↓ 30.07%
Net Income	$-29.5M	↓ 52.32%
Net Profit Margin	-57.18%	↑ 26.69%

	FY18	Y/Y Change
Profit	$184.5M	↓ 224.98%

	FY19	Y/Y Change
Profit	$-27.2M	↓ 114.77%

	FY20	Y/Y Change
Profit	$225.2M	↓ 926.35%

	FY21	Y/Y Change
Profit	$64.2M	↓ 71.47%

	FY22	Y/Y Change
Profit	$48.5M	↓ 24.48%

	FY23	Y/Y Change
Profit	$73.1M	↑ 50.63%

	Q2 FY23	Q/Q Change
Profit	$19.0M	↑ 49.88%

	Q3 FY23	Q/Q Change
Profit	$20.6M	↑ 8.38%

	Q4 FY23	Q/Q Change
Profit	$20.8M	↑ 0.97%

	Q1 FY24	Q/Q Change
Profit	$127.7M	↑ 513.99%

	Q2 FY24	Q/Q Change
Profit	$58.2M	↓ 54.4%

	Q3 FY24	Q/Q Change
Profit	$34.3M	↓ 41.0%

	FY18	Y/Y Change
Operating Cash Flow	$-148.6M	↑ 13.2%
Investing Cash Flow	$140.4M	↓ 491.74%
Financing Cash Flow	$10.7M	↓ 93.46%

	FY19	Y/Y Change
Operating Cash Flow	$-70.3M	↓ 52.68%
Investing Cash Flow	$64.2M	↓ 54.27%
Financing Cash Flow	$136.2M	↑ 1173.56%

	FY20	Y/Y Change
Operating Cash Flow	$-85.2M	↑ 21.09%
Investing Cash Flow	$21.4M	↓ 66.75%
Financing Cash Flow	$201.7M	↑ 48.11%

	FY21	Y/Y Change
Operating Cash Flow	$-263.8M	↑ 209.72%
Investing Cash Flow	$-50.5M	↓ 336.39%
Financing Cash Flow	$268.2M	↑ 32.96%

	FY22	Y/Y Change
Operating Cash Flow	$-174.8M	↓ 33.73%
Investing Cash Flow	$8.1M	↓ 116.05%
Financing Cash Flow	$32.6M	↓ 87.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-24.8M	↓ 54.47%
Investing Cash Flow	$17.5M	↓ 30.0%
Financing Cash Flow	$809.0K	↓ 98.37%

Esperion Therapeutics Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Esperion Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Esperion Therapeutics, Inc.	0.91%	-8.3%	2.79%	-41.38%	-96.07%
Intra-cellular Therapies, Inc.	51.23%	65.01%	87.46%	224.67%	396.26%
Haleon Plc Spon Ads	-4.64%	3.59%	9.87%	24.7%	24.7%
Zoetis Inc.	0.64%	-8.23%	-13.24%	-17.86%	16.88%
Neurocrine Biosciences Inc.	5.79%	-1.39%	2.47%	96.79%	35.64%
Viatris Inc.	-9.74%	-3.17%	-2.92%	-22.81%	-30.84%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Esperion Therapeutics, Inc.	NA	NA	-4.78	-0.3	-2.61	0.04	NA	-1.89
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.88	28.88	1.66	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.84	31.84	2.63	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	37.9	37.9	0.33	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Esperion Therapeutics, Inc.	Buy	$435.4M	-96.07%	NA	-29.37%
Intra-cellular Therapies, Inc.	Buy	$13.4B	396.26%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.7%	28.88	10.75%
Zoetis Inc.	Buy	$76.4B	16.88%	31.84	26.55%
Neurocrine Biosciences Inc.	Buy	$14.5B	35.64%	37.9	17.21%
Viatris Inc.	Hold	$13.5B	-30.84%	224.4	-5.87%

About Esperion Therapeutics

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Organization	Esperion Therapeutics
Employees	240
CEO	Mr. Sheldon L. Koenig
Industry	Health Technology

Management People of Esperion Therapeutics

Name	Title
Mr. Sheldon L. Koenig	President, CEO & Director
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer
Mr. Glenn P. Brame	Chief Technical Operations Officer
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications
Ms. Betty Jean Swartz	Chief Business Officer

Important FAQs about investing in Esperion Therapeutics from India :

What is Esperion Therapeutics share price today?

Esperion Therapeutics share price today stands at $2.21, Open: $2.25 ; Previous Close: $2.26 ; High: $2.31 ; Low: $2.18 ; 52 Week High: $3.94 ; 52 Week Low: $1.58. The stock opens at $2.25, after a previous close of $2.26. The stock reached a daily high of $2.31 and a low of $2.18, with a 52-week high of $3.94 and a 52-week low of $1.58.

Can Indians buy Esperion Therapeutics shares?

Yes, Indians can invest in the Esperion Therapeutics (ESPR) from India.

With INDmoney, you can buy Esperion Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Esperion Therapeutics at zero transaction cost.

How can I buy Esperion Therapeutics shares from India?

It is very easy to buy Esperion Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Esperion Therapeutics be purchased?

Yes, you can buy fractional shares of Esperion Therapeutics with INDmoney app.

What are the documents required to start investing in Esperion Therapeutics stocks?

To start investing in Esperion Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.